SCHEMBL6017212

SCHEMBL6017212

CN1CCNCC1c1ccc2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 4/20 0.47
CYP3A4 P08684 4/20 0.47
CYP1A2 P05177 3/20 0.47
HTR3E A5X5Y0 2/20 0.47
HTR3B O95264 2/20 0.47
HTR3A P46098 2/20 0.47
HTR3D Q70Z44 2/20 0.47
HTR3C Q8WXA8 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MAPK1 P28482 2/20 0.47
PMP22 Q01453 2/20 0.47
USP2 O75604 1/20 0.47
ADRB1 P08588 1/20 0.47
HTR1A P08908 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR7 P34969 1/20 0.47
HTT P42858 1/20 0.47
HTR6 P50406 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8168669 0.82 KDM4E (0.43) KDM4EALDH1A1CYP3A4CYP1A2HTR3E
SCHEMBL9010420 0.81 KDM4E (0.55) KDM4EALDH1A1CYP3A4CYP1A2HTR3E
SCHEMBL15737883 0.79 CYP3A4 (0.43) KDM4EALDH1A1CYP3A4CYP1A2HTR3E
SCHEMBL3585729 0.78 CYP3A4 (0.43) KDM4EALDH1A1CYP3A4CYP1A2HTR3E
SCHEMBL5345232 0.75 HTR2C (0.33) HTR2CTAAR1
SCHEMBL2900748 0.75 PLD1 (0.42) KDM4EALDH1A1HSD17B10HTR1AHTR2C
SCHEMBL8520212 0.73 CCR1 (0.46) KDM4EALDH1A1CYP1A2HSD17B10MAPK1
SCHEMBL28420018 0.72 TAAR1 (0.40) ALDH1A1HTR2CMAPTRAB9AKMT2A
SCHEMBL1579434 0.72 CHRNB2 (0.55) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18913839 0.72 CHRNB2 (0.55) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660079-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA Pharmacia Corporation (US) 2006-05-31 EP disclosed
US-20050085477-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia PHARMACIA CORPORATION 2005-04-21 US disclosed
US-20050080084-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage PHARMACIA CORPORATION 2005-04-14 US disclosed
WO-2005018541-A2 COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
WO-2005018569-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085477-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia TPH2, TPH1, HTR2A KDM4E 2950/4885ALDH1A1 1103/4885CYP3A4 1603/4885
US-20050080084-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage TPH2, TPH1, HTR2A KDM4E 4399/4885ALDH1A1 1946/4885CYP3A4 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.